Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

The Academy of Oncology Nurse & Patient Navigators Voices Support for Cancer Patient Infusions That Might Enhance Protection Against COVID-19
  • USA - English

The Academy of Oncology Nurse & Patient Navigators (AONN+) signed a letter to President Biden urging specific steps to address the special needs of cancer patients and other immune compromised individuals during the COVID-19 pandemic.


News provided by

The Academy of Oncology Nurse & Patient Navigators

Feb 16, 2022, 06:00 ET

Share this article

Share toX

Share this article

Share toX

CRANBURY, N.J., Feb. 16, 2022 /PRNewswire-PRWeb/ -- In the spirit of upholding the patient navigation competency that directs navigators to "facilitate patient-centered care that is compassionate, appropriate, and effective for the treatment of cancer and the promotion of health," the Academy of Oncology Nurse & Patient Navigators (AONN+) Policy and Advocacy committee signed a letter this week addressed to President Joe Biden. The letter, created by the Cancer Leadership Council, focused on the special needs of cancer patients and other immune-compromised individuals during the COVID-19 pandemic and urged action to increase the supply and improve the distribution of monoclonal antibodies and antiviral treatments for pre-exposure prophylaxis and treatment of COVID-19 in immune-compromised individuals.

Some cancer patients are less likely than other people to enjoy the protections provided by the Covid vaccines. For example, blood cancer patients' antibody levels may not be as strong as those in fully vaccinated, healthy adults, and this makes them more susceptible to a COVID-19 breakthrough infection. Their risk is that blood cancers attack the immune system since their cancer arises in cells that create antibody-producing cells. Then, the drugs that attack the leukemia, lymphoma, and multiple myeloma cancer remove not just malignant cells but also benign immune cells. Think of the bone marrow transplants that wipe out an individual's entire immune system and the rebuilding which takes months. Bone marrow transplant patients have to start over with all vaccinations—not just against Covid—to teach those new immune cells to fight the invading coronavirus, flu, or other pathogens.

AONN+ is proud of the stance the leaders in Policy & Advocacy are taking in support of oncology patients!

February 1, 2022

The President
The White House
1600 Pennsylvania Avenue, NW
Washington, DC 20500

Dear Mr. President:

The undersigned organizations represent cancer patients, healthcare professionals, caregivers, and researchers. We are writing you about the special needs of cancer patients and other immune compromised individuals during the COVID-19 pandemic. We urge specific steps to address these needs, including increasing the supply and improving the distribution of monoclonal antibodies and antiviral treatments for pre-exposure prophylaxis and treatment of COVID-19 in immune compromised individuals.

The development of COVID-19 vaccines, monoclonal antibodies, and antivirals, and the approval of existing therapies for COVID-19 use have been impressive achievements during the pandemic. These accomplishments are a testament to the work of talented biomedical researchers and the commitment of innovative biopharmaceutical companies, as well as a statement about the benefits of public and private sector collaboration.

Despite the promise of vaccines and therapeutics, the COVID-19 virus has proven to be a daunting adversary. Patients with hematologic cancers, many cancer patients in treatment, and certain other cancer patients can offer their experience to underscore the challenges associated with COVID-19. Cancer patients, because of their disease or the treatments for their disease, may be immune compromised. This has put them at special risk of contracting COVID-19 and at risk of poor outcomes if they do contract COVID-19.

Cancer patients have sought out vaccination to protect themselves against COVID-19. Many cancer patients and other immune compromised individuals have completed a two-dose series of mRNA vaccine and have taken the third recommended dose for immune compromised individuals. They are also prepared to take a fourth vaccine booster dose.

However, many cancer patients–as a result of their immune compromised status–have a modest response to vaccines. Despite their own efforts to protect themselves against COVID-19, these patients find themselves much as they did at the beginning of the pandemic. They are vaccinated but not protected. They are closely adhering to mitigation strategies including masking, distancing, and working from home where possible. But this means that they are often unable to see family, work in some circumstances, or live as other fully vaccinated individuals can. Of great concern is the impact of their immune compromised status on their ability to undertake and successfully complete cancer treatment.

Fortunately, a monoclonal antibody combination and antivirals might offer additional tools to immune compromised cancer patients. However, the supplies of both the monoclonal antibody combination and antiviral medications are very limited, and available supplies are not consistently distributed to those who could benefit most, according to available evidence. [1]

During the pandemic, federal health officials have communicated constructively with healthcare professionals and researchers, including cancer experts, on topics related to the immune compromised and COVID-19. The approach of federal officials led to prompt action to recommend a third dose of mRNA vaccine as part of the primary series for those who are immune compromised and to the recommendation of a fourth dose as a booster dose. [2]

We urge you to continue this approach to collaboration and communication to meet the needs of the most vulnerable during the pandemic.

Although we are presenting the urgent needs of cancer patients and other immune compromised individuals who would benefit from monoclonal antibodies and antivirals but cannot obtain them, we understand that there is currently lower use of monoclonal antibody treatment among black, Asian, Hispanic, and other races with positive SARS-CoV-2 tests results relative to white and non-Hispanic patients.[3] This disparity in access must also be addressed. These disparities in access are likely experienced by cancer patients who would benefit from monoclonal antibodies. We realize that we, as healthcare professionals and patient advocates, must be engaged in efforts to address the disparities in COVID-19 treatment access. If the issues related to supply and allocation for cancer patients and other immune compromised individuals are addressed, as we urge below, we understand that important actions will still be necessary to ensure that disparities in access to monoclonal antibodies by black, Asian, and Hispanic patients–including those with cancer–are addressed.

We recommend that the federal government increase as much as possible its procurement of the monoclonal antibody combination and antiviral treatments. We also recommend that you consider an allocation and distribution system that would rely on the best available evidence regarding those who would benefit from these products. We can offer the expertise and experience of scientists, researchers, and patient advocates from our organizations to assist in this process. We can also recommend that distribution of these products to cancer centers and hospitals would help ensure better access for cancer patients who are immune compromised and who would benefit from these products.

We stand ready to offer our expertise and experience to address these difficult issues. We know that we share an interest in employing all responsible public health strategies to help vulnerable cancer patients and other immune compromised individuals survive this pandemic.

Sincerely,

Cancer Leadership Council

References:
[1] On January 24, 2022, the Food and Drug Administration (FDA) limited the use of certain monoclonal antibodies due to their limited efficacy against the omicron variant. FDA press release accessed on January 25, 2022: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron. As a result, our recommendations relate to the monoclonal antibody combination marketed as Evusheld.
[2] On January 4, 2022, the Centers for Disease Control and Prevention (CDC) updated its recommendation for a fourth dose, as a booster, for moderately or severely immunocompromised individuals. Recommendation on website accessed on January 25, 2022: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron. Despite the recommendation, immune compromised individuals are being turned away from pharmacies when they seek the fourth dose booster. Liz Szabo of Kaiser Health News reported on January 25, 2022. Article accessed on January 25, 2022: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron.
[3] Wiltz JL, Feehan AK, Molinari NM, et al. Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 – United States, March 202-August 2021. MMWR Morb Mortal Wkly Rep 2022; 71:96-102. Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 — United States, March 2020–August 2021 | MMWR (cdc.gov).

About the Academy of Oncology Nurse & Patient Navigators, Inc. (AONN+)
The Academy of Oncology Nurse & Patient Navigators, Inc. (AONN+), is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. The organization, which has more than 8900 members, was founded in 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services in order to better manage the complexities of the cancer treatment process. http://www.aonnonline.org.

About Amplity Medical Communications
Amplity Medical Communications, formerly The Lynx Group, is a premier medical communications and education company acutely focused on oncology and rare disease states. Amplity Medical Communications specializes in market access to and with advanced practice providers, patients, and their caregivers. With more than 100 years of combined senior leadership experience, Amplity Medical Communications continually creates award-winning medical education and cultivates strong relationships within proprietary brands serving patients and their caregivers, physicians, payers, nurses, pharmacists, navigators, and practice managers. Currently, Amplity Medical Communications partners with more than 50 of the top pharma and biotech companies globally.

Media Contact

Carol Bustos, The Lynx Group, +1 (209) 298-5716, [email protected]

Twitter

SOURCE The Academy of Oncology Nurse & Patient Navigators

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.